Statement from Ambassador Deborah L. Birx, M.D., U.S. Global AIDS Coordinator, on Extension of Medicines Patent Pool's License with Gilead Sciences to Include Tenofovir Alafenamide (TAF)

July 24, 2014

Today’s Medicines Patent Pool (MPP) announcement regarding the extension of its existing license with Gilead Sciences to include tenofovir alafenamide (TAF) is a promising step toward improving access to lifesaving HIV/AIDS treatment. The extended license would avail access to TAF in 112 countries, where more than 92 percent of people living with HIV/AIDS in the developing world reside.

It is important to note that TAF is an investigational drug, which is currently being studied in phase III clinical trials for final efficacy testing. While TAF has not yet been approved for use, the MPP announcement reflects the importance of ensuring rapid access to new lower-dose HIV medicines for people living with HIV/AIDS worldwide and accelerating efforts to control the HIV/AIDS epidemic. U.S. Government interagency website managed by the Office of U.S. Global AIDS Coordinator
and the Bureau of Public Affairs, U.S. State Department.
External Link Policy | Copyright Information | Privacy | FOIA